贝达药业
(300558)
| 流通市值：204.88亿 | | | 总市值：205.44亿 |
| 流通股本：4.22亿 | | | 总股本：4.23亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,975,927,792.57 | 1,039,835,367.29 | 3,609,338,576.55 | 2,717,342,723.91 |
| 营业收入 | 1,975,927,792.57 | 1,039,835,367.29 | 3,609,338,576.55 | 2,717,342,723.91 |
| 二、营业总成本 | 1,650,821,748.41 | 777,633,137.59 | 3,158,280,259.83 | 2,301,749,460.62 |
| 营业成本 | 465,633,880.77 | 217,498,644.75 | 738,658,363.99 | 534,313,542.97 |
| 税金及附加 | 25,127,892.25 | 12,127,471.09 | 44,068,578.36 | 31,561,300.02 |
| 销售费用 | 682,293,273.92 | 320,482,402.21 | 1,298,224,517.2 | 929,022,001.15 |
| 管理费用 | 206,408,921.06 | 102,366,872.15 | 480,458,322.99 | 372,296,453.39 |
| 研发费用 | 216,927,125.02 | 97,439,554.28 | 510,868,058.37 | 372,969,710.8 |
| 财务费用 | 54,430,655.39 | 27,718,193.11 | 86,002,418.92 | 61,586,452.29 |
| 其中:利息费用 | 36,473,441.42 | 17,977,908.51 | 76,137,728.52 | 57,513,928.75 |
| 其中:利息收入 | 1,009,779.38 | 564,568.32 | 4,294,222.11 | 3,925,199.77 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 72,656,728.97 | 24,265,215.19 | -58,682,848.1 | -48,026,625.59 |
| 加:投资收益 | -27,370,062.33 | -9,987,525.66 | -20,643,530.43 | -9,911,270.35 |
| 资产处置收益 | -344,114.22 | 3,310.8 | 377,650.1 | 72,940.02 |
| 资产减值损失(新) | -29,933,433.87 | - | - | - |
| 信用减值损失(新) | -4,483,171.66 | 620,816.83 | 545,181.28 | 689,655.85 |
| 其他收益 | 33,487,008.2 | 5,790,391.04 | 45,728,110.98 | 36,073,974.44 |
| 四、营业利润 | 369,118,999.25 | 282,894,437.9 | 418,382,880.55 | 394,491,937.66 |
| 加:营业外收入 | 76,718.28 | 75,920.02 | 1,013,403.47 | 1,008,120.46 |
| 减:营业外支出 | 880,958.51 | 502,215.26 | 5,033,261 | 3,926,011.16 |
| 五、利润总额 | 368,314,759.02 | 282,468,142.66 | 414,363,023.02 | 391,574,046.96 |
| 减:所得税费用 | 75,624,687.35 | 51,308,540 | 128,154,268.18 | 88,567,954.95 |
| 六、净利润 | 292,690,071.67 | 231,159,602.66 | 286,208,754.84 | 303,006,092.01 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 292,690,071.67 | 231,159,602.66 | 286,208,754.84 | 303,006,092.01 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 302,134,274.28 | 235,916,857.98 | 305,329,161.27 | 316,932,355.32 |
| 少数股东损益 | -9,444,202.61 | -4,757,255.32 | -19,120,406.43 | -13,926,263.31 |
| 扣除非经常损益后的净利润 | 203,403,701.74 | 207,209,518.13 | 327,268,894.14 | 337,227,246.42 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.72 | 0.56 | 0.73 | 0.76 |
| (二)稀释每股收益 | 0.71 | 0.56 | 0.73 | 0.75 |
| 八、其他综合收益 | -275,637,496.56 | -39,992,311.79 | 709,253,597.77 | 43,432,024.6 |
| 归属于母公司股东的其他综合收益 | -275,637,496.56 | -39,992,311.79 | 709,253,597.77 | 43,432,024.6 |
| 九、综合收益总额 | 17,052,575.11 | 191,167,290.87 | 995,462,352.61 | 346,438,116.61 |
| 归属于母公司股东的综合收益总额 | 26,496,777.72 | 195,924,546.19 | 1,014,582,759.04 | 360,364,379.92 |
| 归属于少数股东的综合收益总额 | -9,444,202.61 | -4,757,255.32 | -19,120,406.43 | -13,926,263.31 |
| 公告日期 | 2026-08-21 | 2026-04-23 | 2026-04-23 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |